Validation of NEXLETOL and NEXLIZET by Leading Cardiovascular Societies
Esperion anticipates inclusion in upcoming European Society of Cardiology lipid management guidelines, which would serve as a significant validation of their science and support further clinical adoption.
Cash and cash equivalents ended at $86.1 million, supporting the company’s path to sustainable profitability.
Collaboration revenue decreased 7% year-over-year to $42.1 million, impacted by a prior settlement milestone but grew 105% excluding that milestone.
Esperion achieved its first quarter of operating income from ongoing business of approximately $15 million.
Esperion reported total revenue of $82.4 million for Q2 2025, a 12% increase year-over-year despite a $25 million milestone payment in the prior year quarter.
Research and development expenses decreased 37% year-over-year to $7.2 million, and selling, general and administrative expenses decreased 11% to $39.5 million.
U.S. net product revenue grew 42% year-over-year to $40.3 million and increased 15% sequentially from Q1 2025.
Market Dynamics and Competitive Landscape in Hypert cortisolism and Diabetes
Management discussed the expanding hypercortisolism market, with more players increasing noise and market activity, which they view positively.
The potential launch of a competitor's drug later this year could increase market awareness and demand for cortisol testing and treatment.
In the diabetes space, there are approximately 15 million patients who should have rescue glucagon, but only about 1 million currently do, indicating significant growth opportunities.
Gvoke's collaboration with American Regent for VialDx is expected to enhance market penetration in the coming years.
Expansion of ATTR-CM Study and Its Strategic Implications
The expansion does not impact the previously projected enrollment timeline or cash runway, demonstrating operational efficiency and financial prudence.
The increased enrollment is expected to provide more definitive evidence of nex-z’s efficacy both as a monotherapy and in combination with stabilizers, which is a key market differentiator.
Management emphasizes that this strategic move aligns with their goal of multiple prospective launches by 2030, reinforcing their long-term market strategy.
Strategic Merger of Pelthos and Channel Therapeutics
The merger involved a reverse merger process, creating a new public entity, Pelthos Therapeutics, which launched Zelsuvmi, a treatment for Molluscum contagiosum.
Pelthos's market forecast suggests capturing fewer than 100,000 patients in a 16.7 million patient market, with potential royalties of around $23 million annually in the U.S.
Ligand's strategic ownership of the nitric oxide platform and pipeline of late-stage programs offers multiple future royalty streams, emphasizing its focus on high-value assets.
FDA Label Expansion for EMPAVELI in C3G and Primary IC-MPGN
FDA approved a label expansion for EMPAVELI for patients 12 years and older with C3 myelopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
This is the company's third FDA approval in 4 years, highlighting scientific strength and regulatory success.
The approval enables treatment with a C3-targeting therapy that achieves outcomes across proteinuria reduction, eGFR stabilization, and C3 deposit clearance.
Launch is underway, expanding into rare nephrology and underserved populations, including pediatric patients and post-transplant recurrence.
Reported Q2 revenues of $720 million and adjusted EBITDA of $184 million, with confidence in raising 2025 guidance.
Emphasized diversified portfolio and multiple growth drivers including new product launches, complex medicines, biosimilars, and strategic partnerships.
Projected continued growth with a focus on innovative and affordable medicines, aiming to be America's #1 affordable medicines company.
Dafinchi
